January 25, 2016 – The Institute for Clinical and Economic Review (ICER) released two revised draft reports, Mepolizumab (Nucala®, GlaxoSmithKline) for the Treatment of Severe Asthma with Eosinophilia: Effectiveness, Value, and Value-Based Price Benchmarks and Insulin Degludec (Tresiba®, Novo Nordisk) for the Treatment of Diabetes: Effectiveness, Value, and Value-Based Price Benchmarks, both of which reflect revisions made following a public comment period. The revised drafts include comprehensive reviews of currently available evidence on two new interventions that have triggered significant interest as potential advances in care for patients with either asthma or diabetes. The ICER reports provide analyses of the clinical effectiveness, long-term cost-effectiveness, and potential budget impact of mepolizumab, an injectable drug for patients with severe eosinophilic asthma, and insulin degludec, a long-acting insulin for patients with type 1 or type 2 diabetes mellitus.

ICER is committed to a transparent public engagement process to ensure that all stakeholders have the opportunity to provide input to our evidence reports. After the initial draft ICER reports were released on December 21, 2015, drug manufacturers and other stakeholders had a two-week period to provide comments. ICER staff considered these comments in the development of the revised draft reports, which will be used to support deliberations and voting at the February 12, 2016 public meeting of the California Technology Assessment Forum (CTAF). There will be a limited amount of time available during the public meeting for anyone wishing to make an oral comment on the report. Requests to make oral comments should be submitted to ctaf@icer-review.org by Friday, February 5, 2016.

More information on our methods for public engagement can be found here.

Based on comments received, the revised drafts contain updated information. Each report is accompanied by the public comments received, as well as a description of how comments were considered in revisions to the draft reports. You can access the revised draft report on mepolizumab, public comments received, the accompanying response to comments, and voting questions here. The revised draft report on insulin degludec and accompanying materials are available here.

CTAF Meeting Details 

Date: February 12, 2016

Location: The California Endowment Oakland Conference Center

1111 Broadway, 7th Floor

Oakland, CA 94607

Click here to register to view a live webcast of the meeting. A video recording will be available on the CTAF website after the meeting.